Press Releases

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Press Releases

Date Title
09/18/20 Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 European Society for Medical Oncology (ESMO) Virtual Congress
09/14/20 Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience
09/09/20 Alkermes to Take Part in Cantor Virtual Global Healthcare Conference
09/08/20 Alkermes to Present New Data on Investigational Immuno-Oncology Candidate, ALKS 4230, at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress
08/21/20 Virtual FDA Advisory Committee Meeting to Review New Drug Application for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder Tentatively Scheduled for Oct. 9, 2020
08/19/20 Alkermes Initiates Phase 2 Study Designed to Evaluate Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Patients with Advanced Solid Tumors
08/17/20 American Journal of Psychiatry Publishes Data From Alkermes' Phase 3 ENLIGHTEN-2 Weight Study of ALKS 3831 in Patients With Schizophrenia
07/29/20 Alkermes Releases Third Annual Corporate Responsibility Report
07/29/20 Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations
07/27/20 New Harris Poll Survey Offers Insights into Potential of Telepsychiatry During and After the COVID-19 Pandemic
07/22/20 Alkermes to Host Conference Call to Discuss Second Quarter 2020 Financial Results
06/29/20 Alkermes Announces Launch of 3rd Annual Alkermes Pathways Research Awards® Program
06/24/20 Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities
06/22/20 New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
06/04/20 Alkermes to Take Part in 41st Annual Goldman Sachs Global Healthcare Conference
06/02/20 Alkermes Response to Current Events
05/27/20 Alkermes Highlights New Data From Schizophrenia Portfolio at the American Society of Clinical Psychopharmacology 2020 Annual Meeting
05/20/20 Journal of Clinical Psychiatry Publishes Data from Alkermes' ALPINE Study in Patients With Schizophrenia
05/15/20 Statement from Alkermes on Response to COVID-19
05/14/20 Alkermes Presents New Data From Schizophrenia Portfolio at Virtual 2020 Congress of the Schizophrenia International Research Society
05/11/20 Alkermes Announces Expansion of Patient Services and Provider Network to Support Uninterrupted Access to ARISTADA® and VIVITROL® During COVID-19 Crisis
05/06/20 Alkermes Announces Upcoming Presentation at the Bank of America Securities Virtual Health Care Conference
05/04/20 Alkermes Launches COVID-19 Relief Fund to Support Innovative Programs Helping Vulnerable Patient Communities
04/29/20 Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update
04/22/20 Alkermes to Host Conference Call to Discuss First Quarter 2020 Financial Results
04/22/20 Alkermes Announces Publication of Preclinical Data for ALKS 4230 in the Journal for ImmunoTherapy of Cancer
03/04/20 Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia
02/24/20 Alkermes Response to Media Coverage of the Company and VIVITROL
02/24/20 Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 40th Annual Health Care Conference
02/19/20 Alkermes to Present at the 9th Annual SVB Leerink Global Healthcare Conference
02/13/20 Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2019 and Provides Financial Expectations for 2020
02/06/20 Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results
01/28/20 Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder
01/08/20 Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference